RecruitingInterventionalPhase 1Last updated Aug 10, 2026

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.

Overview

ClinicalTrials.gov ID: NCT07755436
Lead Sponsor: ArriVent BioPharma, Inc.INDUSTRY
Brief Summary: This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.
Study Type: Interventional

Status

Overall Status: Recruiting
Start Date: Jul 23, 2026Actual
Primary Completion Date: Aug 2027Estimated
Completion Date: May 2029Estimated

Study Record Dates

First Submitted: Aug 5, 2026
First Submitted that Met QC Criteria: Aug 5, 2026
First Posted: Aug 10, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 5, 2026
Last Update Posted: Aug 10, 2026Actual
Last Verified: Aug 2026

NCT05940844Withdrawn

Study of OB-002 in Patients With Refractory Metastatic Cancer

NCT05538624Terminated

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

NCT02539719Terminated

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

NCT07462468Not yet recruiting

A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

NCT03748186Completed

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

NCT04493619Terminated

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer